Summary & Overview
HCPCS A9539: Technetium Tc-99m Pentetate, Diagnostic Study Dose
Headline: HCPCS Level II code A9539 denotes technetium Tc-99m pentetate for diagnostic nuclear medicine studies
Lead: HCPCS Level II code A9539 captures a specific radiopharmaceutical — technetium tc-99m pentetate — supplied per study dose up to 25 millicuries for diagnostic imaging. The code identifies a common tracer used in nuclear medicine protocols and is central to billing for radiopharmaceutical services across clinical settings.
What the code represents and national importance: Radiopharmaceuticals coded under HCPCS are essential for diagnostic imaging workflows. A9539 designates a defined per-study dose of Tc-99m pentetate, supporting standardized billing and inventory tracking for studies such as renal imaging and other nuclear medicine procedures. Consistent coding for radiotracers impacts claims processing, reimbursement, and utilization reporting nationwide.
Key payers covered: This review covers national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks and coding context for A9539, outlines typical clinical settings and service lines where the agent is used, and summarizes payer coverage considerations where available. It highlights operational and billing implications for facilities that administer Tc-99m pentetate, and identifies where input data is not available. Data not available in the input includes payer-specific reimbursement rates, associated taxonomies, ICD-10 diagnoses, and related procedure codes.
Billing Code Overview
HCPCS Level II code A9539 represents Technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries. This code is used for a radiopharmaceutical diagnostic agent containing technetium Tc-99m pentetate administered for nuclear medicine imaging studies. The service type is a diagnostic radiopharmaceutical administration used to obtain nuclear medicine images for clinical evaluation. The typical site of service is nuclear medicine departments, outpatient imaging centers, and hospital radiology suites where diagnostic radiotracer studies are performed.
Clinical & Coding Specifications
Clinical Context
A typical adult patient presents to the outpatient nuclear medicine department with a clinical question of cerebrospinal fluid (CSF) leak localization or evaluation of cerebrospinal fluid flow dynamics. The patient has symptoms such as positional headache, clear rhinorrhea suspicious for CSF otorrhea/rhinorrhea, or post-lumbar-puncture headache that has not responded to conservative measures. A radionuclide cisternography study using A9539 (Technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries) is ordered by the referring neurologist or neurosurgeon.
Workflow:
-
Referral and order entry: The referring clinician documents indication (e.g., suspected CSF leak) and relevant ICD-10 diagnosis code on the order.
-
Pre-procedure preparation: The nuclear medicine team obtains informed consent, reviews allergies and recent imaging, and confirms no pregnancy. Intrathecal administration requires sterile lumbar puncture technique performed by an appropriately credentialed clinician (radiologist, neurologist, or neurosurgeon).
-
Procedure: A lumbar puncture is performed under sterile conditions;
Technetium tc-99m pentetateis prepared and a study dose (up to 25 mCi) is injected intrathecally. Serial planar and/or SPECT images are acquired over several hours to days to assess CSF flow or detect extra‑cranial tracer leakage. -
Post-procedure care: The patient is observed per facility protocols for complications (headache, back pain, infection). Imaging results are interpreted by the nuclear medicine physician and correlated with clinical findings for surgical planning or further management.
Typical site of service: Outpatient nuclear medicine department, hospital radiology / nuclear medicine suite, or ambulatory surgical center if lumbar puncture requires sedation or IR support.